Protara Therapeutics
TARA
30 hedge funds and large institutions have $14.6M invested in Protara Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 2 closing their positions.
100% more call options, than puts
Call options by funds: $4K | Put options by funds: $2K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
1.79% less ownership
Funds ownership: 50.25% → 48.46% (-1.8%)
3% less funds holding
Funds holding: 31 → 30 (-1)
16% less capital invested
Capital invested by funds: $17.4M → $14.6M (-$2.76M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$267K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.5K |
| 3 |
BlackRock
New York
|
+$2.71K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$707 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$420 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$678K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$491K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$130K |
| 4 |
Millennium Management
New York
|
-$65K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$48.8K |
TARA Hedge Fund Activity: Q4 2022 in Review
30 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2022, worth a combined $14.6M — down 16% from $17.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TARA positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Privium Fund Management (UK), adding an estimated $267K. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $678K sold.
- 30 institutional investors held Protara Therapeutics (TARA) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $14.6M of Protara Therapeutics stock for Q4 2022, down 16% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Protara Therapeutics buyer in Q4 2022 was Privium Fund Management (UK), an estimated $267K added.
- The largest Protara Therapeutics seller in Q4 2022 was Financial Advocates Investment Management, an estimated $678K sold.
Based on aggregated 13F filings for Q4 2022.